Chimeric PARP-Wee1 Inhibitors for Drug-Resistance Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges due to drug resistance and the complexity of cancer pathways, with single-agent and combination therapies exhibiting drawbacks such as drug-drug interactions and high costs.
Innovation Solution
Development of dual inhibitors targeting both poly (ADP-ribose) polymerase (PARP) and Wee1 enzymes, comprising specific compounds with a PARP inhibitor and a Wee1 inhibitor connected by a linker, to synergistically combat cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapies targeting multiple pathways are used, then anticancer efficacy is improved, but device complexity and drug-drug interactions increase
Solution Approach 1:
The patent combines two distinct therapeutic agents (PARP inhibitor and Wee1 inhibitor) into a single chimeric molecule through chemical linkage. This merging approach maintains the synergistic anticancer effects of dual pathway inhibition while eliminating the need for separate administration of multiple drugs, thereby reducing therapy complexity and potential drug-drug interactions.
Solution Approach 2:
The chimeric compound serves multiple functions simultaneously: it acts as both a PARP inhibitor and a Wee1 inhibitor within a single molecular entity. This multi-functionality allows the compound to target multiple cancer pathways (DNA repair and cell cycle control) while being administered as a single agent, resolving the contradiction between efficacy and complexity.
2Device complexity
If single-agent therapies are used, then device complexity is reduced, but drug resistance develops
Solution Approach 1:
The chimeric compound merges two mechanisms of action (PARP inhibition and Wee1 inhibition) into one agent. This allows the single drug to simultaneously disrupt DNA repair pathways and cell cycle progression, preventing cancer cells from developing resistance through a single mechanism while maintaining simplicity of administration.
Solution Approach 2:
The invention creates a composite molecular structure combining pharmacophores for both PARP and Wee1 inhibition. This composite approach enables the single agent to exert multiple therapeutic effects, addressing drug resistance issues typically associated with single-target therapies while maintaining the simplicity of single-agent administration.
3Reliability
If combination therapies are used, then anticancer efficacy is improved, but manufacturing cost and development time increase
Solution Approach 1:
By merging two therapeutic functions into one chimeric compound, the invention eliminates the need for separate development, approval, and manufacturing processes for two distinct drugs. This reduces development time and manufacturing costs while maintaining the enhanced efficacy of dual pathway inhibition.
Solution Approach 2:
The multi-functional chimeric compound serves as both a PARP inhibitor and Wee1 inhibitor, allowing a single drug development program to achieve what would traditionally require two separate drug development programs, thereby reducing overall development and manufacturing costs.
Data Source
AI summary
The present invention is generally directed to dual inhibitors of poly (ADP-ribose) polymerase (PARP) and Wee1 useful in the treatment of diseases and disorders modulated by said enzymes and having the Formula (A):P-L-W (A),wherein P is new or known inhibitor of poly (ADP-ribose) polymerase (PARP); L is a linker that connected two active parts of the molecule and may be indeed the part of one of these active molecules; W is new or known inhibitor of Wee1; and in more specific aspect directed to compound of the Formula (I):